INmune Bio, Inc.INMBNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
63.60%
↓ 41% below average
Average (9y)
107.27%
Historical baseline
Range
High:328.95%
Low:-16.92%
Volatility
322.4%
High variability
| Period | Value |
|---|---|
| 2024 | 63.60% |
| 2023 | 18.78% |
| 2022 | -16.92% |
| 2021 | 247.19% |
| 2020 | 80.29% |
| 2019 | 197.01% |
| 2018 | 153.81% |
| 2017 | 328.95% |
| 2016 | 0.00% |
| 2015 | 0.00% |